RAD-x continues German expansion - Gilde Healthcare

RAD-x continues German expansion

April 17, 2018

Utrecht, The Netherlands – Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging centres in Germany. The combination with RAD-x enables TelradKo to accelerate its expansion and continue investing in the latest technology to establish itself as the leading provider of teleradiology services to small and medium sized hospitals.

 

About RAD-x

RAD-x is a fast-growing pan-European operator of diagnostic imaging centres, based on a network of local and regional centres. The network currently has a staff of over 350 healthcare professionals working in diagnostic imaging centres and hospitals. RAD-x’s growth model is based on the integration in its network of existing leading local and regional medical imaging centres and offering their radiologists to become shareholders of RAD-x. For more information, visit the company’s website at www.RAD-x.eu

About TelradKo

TelradKo is a provider of teleradiology services to hospitals and hospital-based imaging centres in Germany founded in 2014. For more information, visit the company’s website at www.telradko.de

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
March 21, 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
March 18, 2024